Epigenetic modulation of Gremlin-1/NOTCH pathway in experimental crescentic immune-mediated glomerulonephritis

Lucia Tejedor-Santamaria [1,2], **José Luis Morgado-Pascual** [1,2], **Laura Marquez-Exposito** [1,2], **Beatriz Suarez-Alvarez** [2,3] , **Raul R. Rodrigues-Diez**[2,3], **Antonio Tejera-Muñoz**[1,2], **Vanessa Marchant**[1,2] **Sergio Mezzano**[5], **Carlos López-Larrea** [2,3], **Anna Sola**[6], **Gema Maria Fernandez-Juarez**[7], **Alberto Ortiz** [2,4] , **Sandra Rayego-Mateos** [1,2$] , **Marta Ruiz-Ortega** [1,2$*]

1 Cellular Biology in Renal Diseases Laboratory. IIS-Fundación Jiménez Díaz-Universidad Autónoma Madrid. Spain.
2 REDINREN Spain.
3 Department of Immunology. Hospital Universitario Central de Asturias. Oviedo. Spain.
4 Division of Nephrology and Hypertension. IIS-Fundación Jiménez Díaz-Universidad Autónoma Madrid. Spain.
5 Universidad Austral Chile. Valdivia. Chile
6 Department of Experimental Nephrology. IDIBELL. Barcelona. Spain.
7 Unidad de Nefrología. Hospital Universitario Fundación Alcorcón.

$ equal contribution of senior authors

* Correspondence: Marta Ruiz-Ortega, Cellular Biology in Renal Diseases Laboratory. IIS- Fundación Jiménez Díaz, Avda. Reyes Católicos, 2 28040 Madrid Spain Email: mruizo@fjd.es

Abstract: Crescentic glomerulonephritis is a devastating autoimmune disease that without early and properly treatment may rapidly progress to end-stage renal disease and death. Current immunosuppressive treatment provided limited efficacy and an important burden of adverse events. Epigenetic drugs are a source of novel therapeutic tools. Among them, bromodomain and extraterminal domain (BET) inhibitors (iBETs) block the interaction between bromodomains and acetylated proteins, including histones and transcription factors. iBETs have demonstrated protective effects on malignancy, inflammatory conditions and experimental kidney disease. Recently, Gremlin-1 was proposed as a urinary biomarker of disease progression in human anti-neutrophil cytoplasmic antibody (ANCA)-associated crescentic glomerulonephritis. We have now evaluated whether iBETs regulate Gremlin-1 in experimental anti-glomerular basement membrane nephritis induced by nephrotoxic serum (NTS) in mice, a model of human crescentic glomerulonephritis. In NTS-injected mice, the iBET JQ1 inhibited renal Gremlin-1 overexpression and diminished glomerular damage, including podocyte loss. Chromatin immunoprecipitation assay demonstrated BRD4 enrichment of the *Grem-1* gene promoter in injured kidneys, consistent with Gremlin-1 epigenetic regulation. Moreover, JQ1 blocked BRD4 binding and inhibited *Grem-1* gene transcription. The beneficial effect of iBETs was also mediated by targeting NOTCH signaling pathway. JQ1 inhibited the gene expression of the NOTCH effectors *Hes-1* and *Hey-1* in NTS-injured kidneys. Our results further support the role for epigenetic drugs, such as iBETs, in the treatment of rapidly progressive crescentic glomerulonephritis.

Keywords: crescentic glomerulonephritis; chronic kidney disease, Bromodomain; BET proteins; Gremlin, NOTCH

1. Introduction

Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function, present for >3 months, with implications for health [1]. CKD is projected to become the 5th global cause of death by 2040 [2], revealing the importance of research in this area [3]. Glomerular kidney disease cause 18% of CKD cases requiring kidney replacement therapy, illustrating the failure of current therapeutic approaches to prevent CKD progression to end-stage renal disease (ESRD) [4]. Rapidly progressive glomerulonephritis (RPGN) is one of the most aggressive forms of CKD, characterized by proliferation of intrinsic glomerular cells in the Bowman's space, leading to the formation of crescents that evolve to fibrotic structures and loss of functioning glomeruli [5]. Thus, the underlying kidney structural damage for the clinical presentation termed RPGN is cres-

centic glomerulonephritis (cGN). Most GN are immune-mediated, related to presence of anti-neutrophil cytoplasmic antibodies (ANCA), anti-glomerular basement membrane (anti-GBM) antibodies or local immune-complex deposition. Most patients are treated with immunosuppressive therapy, but the residual risk of ESRD remains high despite treatment [2].

Epigenetic mechanisms, especially DNA methylation and post-translational histone modifications, are dynamic processes that regulate gene expression differentially in normal and diseased states. Novel approaches targeting protein-protein interactions of epigenetic 'readers' have been emerged as a novel source of therapeutic drugs. The bromodomain (BRD) and extraterminal (BET) protein family (that includes BRD2, BRD3, BRD4 and BRDT) recognize acetylated lysine residues on core histones, and regulate gene transcription through the recruitment of coactivator proteins involved in transcriptional initiation and elongation, acting as epigenetic 'readers' [6]. BET proteins can also bind to acetylated lysine residues on transcription factors, thus also regulating gene transcription [7]. Selective inhibitors of BET proteins (iBETs), such as the small molecule JQ-1, displace bromodomain binding to acetyl-lysine residues on histones and non-histones proteins [9, 10]. Different iBETs have protected mice from malignancy and experimental inflammation, including from renal diseases [11, 12].

ANCA-associated vasculitis is the major cause of RPGN [5, 15]. We recently described that Gremlin-1 is a potential urinary biomarker of human ANCA-associated cGN [13]. High urinary levels of Gremlin-1 were associated with a more severe disease activity as represented by the number of glomerular crescents, tubulointerstitial fibrosis and interstitial inflammation. Gremlin-1 belongs to the cysteine knot superfamily of proteins and has been proposed as a biomarker and therapeutic target in renal diseases [14]. In the kidney, Gremlin-1 activates several downstream pathways, including nuclear factor-κB (NF-κB) and NOTCH, linked to inflammation and kidney injury [22–25]. The NOTCH signaling pathway is activated in CKD, including glomerular diseases such as diabetic kidney disease (DKD), IgA nephropathy, and focal segmental glomerulosclerosis (FSGS) [26–30]. Activation of NOTCH is mediated by successive proteolytic cleavages of the NOTCH receptor that release its intracellular domain (NICD) from the cellular membrane. Then, NICD is translocated into the nucleus, where it forms a nuclear complex with the transcriptional activator RBP-Jκ (Recombination Signal-binding Protein 1 for J-kappa) and activates the transcription of downstream NOTCH target genes, including the effectors of this pathway Hes (hairy and enhancer of split) and Hey (Hes-related proteins) [23]. *In vivo,* administration of recombinant Gremlin-1 into murine kidneys increased N1ICD nuclear levels and upregulated *Hes-1* gene expression. Moreover, NOTCH inhibition blocks several deleterious actions of Gremlin-1 in the kidney *in vivo* and *in vitro* [22, 24, 25], illustrating the complex relation between Gremlin-1 and NOTCH.

The model of anti-glomerular basement membrane (GBM) induced by nephorotoxic serum (NTS) administration in mice is a model commonly used to study mechanisms of human cGN [24]. We have recently observed that in NTS- injected mice treatment with JQ1 restored changes in renal function, ameliorated glomerular lesions and diminished renal inflammatory cell infiltration, by mechanisms that involved direct inhibition of several proinflammatory genes, as well as blockade of the NF-κB pathway activation and, therefore, the subsequent transcription inhibition of related-genes [25].

The aim of this paper was to evaluate whether iBETs regulate Gremlin-1 in NTS mice, trying to define the final targets of bromodomain/acetyl-lysine binding, subsequent molecular interactions and gene transcription regulation, with special attention to the NOTCH pathway. This study could help to develop better therapeutic tools for the treatment of cGN.

2. Results

2.1. BET inhibition ameliorates renal damage in experimental nephrotoxic nephritis.

The model of NTS administration in mice is commonly used to study mechanisms of human cGN. This model is characterized by proliferation of intrinsic glomerular cells in the Bowman's space, mesangial fibrosis and podocyte damage, resulting in the rapid loss of renal function, resembling the human disease [24]. We previously described that JQ1 ameliorates impaired renal function and glomerular lesions in this model [25] (Figure 1A). NTS-injured kidneys also presented macrophage infiltration that was significantly diminished by JQ1 treatment (Figure 1B). To further evaluate glomerular damage, healthy podocytes, that express Wilms' tumor protein 1 (WT-1), were evaluated. NTS administration in mice, resulted in a dramatic loss of glomerular WT1+ cells, that was restored by JQ1 (Figure 1B).

Figure 1. JQ1 diminishes renal damage in nephrotoxic nephritis. Glomerulonephritis was induced in C57Bl/6 mice by the administration of NTS, and mice were studied 10 days later. Mice were treated daily with JQ1 (100 mg/kg/day) or vehicle, starting before the first NTS-injection. In paraffin-embedded kidney sections renal morphology was evaluated by (A) Masson trichrome staining and (B) immunohistochemistry with specific antibodies. JQ1 ameliorates glomerular damage (A), diminished glomerular monocyte inflammatory cell infiltration (F4/80+ monocytes/macrophages/dendritic cells) and restored healthy podocyte number (WT1+ cells) (B) to values similar to control untreated mice. Figure C shows the quantifications of immunohistochemistry staining (F4/80+ and glomerular WT1+ cells). Data are expressed as the mean±SEM of 5-7 animals per group. *p<0.05 *vs.* control; #p<0.05 *vs.* NTS-injected mice. Panel B shows a representative animal from each group (200x magnification), including a detail of glomeruli.

2.2. Gremlin-1 is overexpressed in experimental nephrotoxic nephritis in mice: Effect of BET inhibition

Kidney injury in mice with NTS nephritis is characterized by the upregulation of Gremlin-1 at the gene and protein levels compared to healthy control mice (Figure 2A-C). Treatment with JQ1 significantly diminished *Grem-1* mRNA levels (Figure 2).

Figure 2. JQ1 diminishes renal Gremlin-1 overexpression at the gene and protein levels in nephrotoxic **nephritis.** Glomerulonephritis was induced in mice that were treated daily with JQ1 (100 mg/kg/day) or vehicle, starting before the first NTS injection. (A) RNA was isolated

from frozen whole kidney samples, and *Grem-1* gene expression levels were evaluated by real-time qPCR. (B) Protein levels of Gremlin-1 were quantified by western blot in total kidney extracts. The figure shows representative blots where GAPDH was used as loading control. (C) Quantification of Western blots. Data are expressed as the mean±SEM of 5 -7 animals per group. *p<0.05 *vs.* control; #p<0.05 *vs.* NTS-injected mice. Figure B show a representative animal from each group.

2.3. Gremlin-1 is a specific target of BET inhibition

Chromatin immunoprecipitation (ChIP) assays demonstrated that BRD4 binding to the promoter region of *Grem-1* was increased in NTS-injured kidneys compared to controls. However, BRD4 enrichment was nearly abolished in JQ1-treated mice (Figure 3). Moreover, inhibition by JQ1 of the recruitment and binding of BRD4 to this promoter region reduced the transcription of *Grem-1*. These results demonstrate that BRD4 directly binds to the regulatory region of *Grem-1* promoting its gene expression, clearly showing that *Grem-1* is a direct target of JQ1.

Figure 3. *Grem-1* is a direct target of iBETs. ChIP assays were performed in renal samples from NTS mice treated or not with JQ1 using an antibody specific for BRD4 or normal rabbit IgG, the latter being a negative control. Enrichment of BRD4-binding regions in the promoter of mouse *Grem-1* was quantified by qPCR using specific primers. Data are from two independent experiments and each pPCR was run in triplicate. Results are expressed as the n-fold enrichment of anti-BRD4 antibody relative to the negative control antibody (considered to be 1). *p<0.05 *vs.* control; #p<0.05 *vs.* NTS-injected mice.

2.4. JQ1 inhibits the NOTCH pathway in experimental nephrotoxic nephritis

NOTCH-1 signaling pathway activation is associated to changes in receptors, ligands and final effector expression levels in preclinical studies and in human samples [19–23, 26, 27]. Real time PCR showed upregulation of the downstream NOTCH-target genes *Hes-1* and *Hey-1* genes in injured kidneys of NTS mice compared to healthy controls (Figure 4 A-B). In contrast, there were no differences in the expression of the NOTCH-1 canonical ligand and activator, *Jagged-1* [28], and in mRNA levels of the noncanonical ligand *Dlk-1*, an endogenous inhibitor reexpressed in kidney diseases [27] (Figure 4C-D). There were also no differences in the expression of NOTCH receptors *Notch-1*, *Notch-2*, *Notch-3* and *Notch-4* between NTS-injured kidneys and controls (Figure 4E-H). Importantly, in NTS mice treatment with JQ1 inhibited the gene overexpression of the Notch effectors *Hes-1* and *Hey-1* (Figure 4 A-B).

Figure 4. JQ1 inhibited NOTCH signaling pathway activation in experimental nephrotoxic nephritis. NTS mice were treated daily with JQ1 (100 mg/kg/day) or vehicle. (A) RNA was isolated from frozen samples of whole kidney, and *Hes-1* (A) *Hey-1*, (B) *Jagged-1* (C), *Dlk-1* (D), *Notch 1* (E), *Notch 2* (F), *Notch 3* (G) and *Notch 4* (H) gene expression levels were evaluated by real-time qPCR. Data are expressed as the mean±SEM of 5 -7 animals per group. *p<0.05 *vs.* control; #p<0.05 *vs.* NTS-injected mice.

2.5. Differential gene expression in experimental nephrotoxic nephritis: impact of BET inhibition

We have further evaluated the effect of BET inhibition on gene expression in experimental nephrotoxic nephritis. In a previous study we demonstrated the JQ1 inhibited the expression of the proinflammatory factors *Ccl-2*, *Ccl-5*, and *Il-6* in NTS-mice by the inhibition of BRD4 binding to their promoter regions [25]. To extend these findings, we have now evaluated whether BET inhibition can modulate other proinflammatory and profibrotic factors in NTS mice. The gene expression of *Il10* and *Cxcl2* were markedly upregulated in injured kidneys, and significantly diminished by JQ1 treatment (Figure 5A and B). The M1 macrophage marker, *Arg2*, and the profibrotic factor *Pai-1* were slightly increased in injured kidneys but their gene expression was significantly inhibited by JQ1 (Figure 5C-D). In contrast, the profibrotic factor *Tgf-β1* and the M2 macrophage marker, *Cd163* were not changed in the NTS mice 10 days after immunization (Figure 5E-F).

Figure 5. Effect of BET inhibition on gene expression in nephrotoxic **nephritis.** RNA was isolated from frozen samples of whole kidney, *IL10* (A) *Cxcl2,* (B*) Cd163* (C)*, Arg2* (D), *Tgf-β* (E) and *Pai1* (F), gene expression levels were evaluated by real-time qPCR. Data are expressed as the mean±SEM of 5 -7 animals per group. *p<0.05 vs. control; #p<0.05 vs. NTS-injected mice.

2.6. BET inhibition diminished the renal expression of the chemokine Ccl-8 in experimental anti-glomerular basement membrane nephritis

The chemokine (C-C motif) ligand 18 (CCL18) has been recently proposed as a potential biomarker of human cGN [29], therefore we evaluated the expression of *Ccl8*, the murine functional human CCL18 homologue [30, 31]. In NTS mice, *ccl8* gene expression was upregulated in injured kidneys and diminished by JQ1 treatment (Figure 6A). Moreover, kidney CCL8 protein levels assayed by ELISA, were significantly elevated in NTS mice and also decreased by JQ1 (Figure 6B).

Figure 6. JQ1 diminishes kidney CCL8 levels in the nephrotoxic nephritis. Glomerulonephritis was induced by NTS administration in mice that were treated daily with JQ1 (100 mg/kg/day) or vehicle, starting before the first NTS injection. (A) RNA was isolated from frozen samples of whole kidney, and *Ccl8* gene expression levels were evaluated by real-time qPCR. (B) CCL8 protein levels were evaluated in total protein of renal extracts by ELISA. Data are expressed as the mean±SEM of 5 -7 animals per group. *$p<0.05$ *vs.* control; #$p<0.05$ *vs.* NTS.

2.7. BET inhibition downregulates Gremlin-1 expression in other models of renal fibrosis

In human cGN, Gremlin-1 overexpression has been described in glomerular and tubulointerstitial areas [32]. We have further evaluated whether BET inhibition can modulate Gremlin-1 in other experimental models of progressive renal disease. To this aim, we studied the model of unilateral ureteral obstruction (UUO). This model is characterized by tubulo-interstitial fibrosis, observed as early as 5 days followed renal injury [33]. We have previously described that JQ1 ameliorates renal inflammation in this model [25]. Treatment with JQ1 significantly diminished *Grem-1* gene expression in obstructed kidneys compared to untreated-obstructed ones (Figure 7).

Figure 7. JQ1 diminishes Gremlin-1 in an experimental model of progressive tubulointerstitial fibrosis. Unilateral ureteral obstruction (UUO) was induced in mice and kidneys were studied after 5 days. Some mice were treated with JQ1 (100 mg/kg/day, i.p. starting 24 hours before UUO. RNA was obtained from total renal extracts and *Grem-1* mRNA levels were determined by RT-qPCR. Data are expressed as the mean±SEM of 5 -7 animals per group. *$p<0.05$ *vs.* control; #$p<0.05$ *vs.* UUO.

3. Discussion

The main finding of this paper is the description of Gremlin-1 as a specific target gene of BET inhibition in the NST-induced experimental model that resembles human progressive cGN. We have recently described that Gremlin-1 is a potential urinary biomarker of human ANCA positive GN [13]. The current therapy for cGN, intense immunosuppression, is not universally effective in preventing progression to ESRD and death, remarking the need for novel therapeutic approaches. Our data support future research to evaluate whether iBETs could be a therapeutic option for cGN.

Selective iBETs, such as JQ1, block the interaction between BET proteins and acetylated proteins, mainly histones and transcription factors [10]. Early studies using iBETs have demonstrated protective effects in malignancy, dependent on inhibition of proto-oncogene transcription and modulation of cancer cell proliferation [8,34]. More recently iBETs have shown beneficial responses in a wide range of inflammatory diseases [9], mainly through modulation of the NF-κB pathway and blocking proinflammatory-related gene expression, as well as inhibiting the Th17/IL17 immune response [10], as we have described in different models of experimental renal diseases, including the NTS nephritis [25]. Now, we have found that JQ1 inhibited the Gremlin-1/NOTCH signaling pathway, thus identifying a novel mechanism of the beneficial effects of iBETs in experimental kidney diseases. Moreover, chromatin immunoprecipitation assays demonstrated that JQ1 modulates BRD4 binding to the promoter region of *Grem-1* gene, thus reducing *Grem-1* transcription, showing that this gene is a specific target of BET inhibition and clearly demonstrating the epigenetic regulation of Gremlin-1 during experimental GN.

Gremlin-1 has been proposed as a mediator and potential therapeutic target in CKD [14]. The *de novo GREM1* expression has been described in several human kidney diseases, including RPGN, DKD, and in kidney transplant-rejection [32,35,36]. Experimental gain- and loss-of-function studies targeting *Grem-1* in renal cells as well as in murine models of kidney disease, by gene silencing or overexpression, have demonstrated the key role of Gremlin-1 in the regulation of inflammation and fibrosis-related processes [17,37–41]. Moreover, administration of recombinant Gremlin-1 to mice caused an early kidney inflammatory response [16], and RNA sequencing analysis revealed changes in biomarkers of kidney damage and wound healing pathways [42]. In human ANCA-associated cGN, Gremlin-1 is overexpressed in glomerular crescents, and in tubular and infiltrating interstitial cells [32], and has been proposed as a potential urinary biomarker [13]. CCL18 is other proposed biomarker of disease activity in ANCA-associated cGN [29]. This chemokine is one of the most highly expressed in human chronic inflammatory diseases, including allergies, fibrotic disorders and certain cancers [43], and is secreted in high amounts by M2 macrophages [44]. The functional analogue of human CCL18 is mouse *Ccl8* and both share CCR8 as functional receptor [30,31]. Interestingly, CD163+/CCL18 expressing macrophages colocalized with Gremlin-1 protein expression in ANCA-associated cGN patients [13]. CD163 is another marker of M2-macrophages and soluble urinary CD163 is a potential biomarker of macrophage activation in different diseases, including cGN [30]. In ANCA-associated cGN, urinary CD11b+ and CD163+ correlated with leukocyte recruitment in the kidney [45], and urinary sCD163 was a biomarker of active renal vasculitis and relapse [46]. We now show that in experimental NTS nephritis, JQ1 decreases kidney *Grem-1* and *Ccl8* and this was associated to milder macrophage cell infiltration and amelioration of kidney damage, and therefore supporting their use as biomarkers of disease progression.

The role of NOTCH pathway in kidney inflammation and CKD progression has been extensively described [18,23,28]. Activation of NOTCH has been described in several human glomerulopathies, including cGN [20,47–49]. In rat anti-GBM rapidly progressive GN, *Notch3* and *Hey-1* mRNAs were upregulated [49]. In murine NTS-nephritis used here, *Hes-1* and *Hey-1* mRNAs were overexpressed at 10 days [27]. BET proteins

interact with the NOTCH pathway. In cancer cells BRD4 bound Jagged-1 and NOTCH1 promoters, increasing the expression of both components and, thus, NOTCH pathway activation, which promotes proliferation and migration in tumors. In addition, I-BET151 impedes BRD4 binding to the NOTCH1 promoter, diminishing the expression of *Hes1* and cancer-cell renewal activity [50,51]. Accordingly, we observed that JQ-1 downregulated *Hes-1* and *Hey-1* expression in NTS mice. In tumor cells, c-MYC directly activates RBPJκ, and subsequent target genes, in a NOTCH activation-independent manner, mediated by CDK9, a component of positive transcription elongation factor b (P-TEFb). Treatment with JQ-1 in these cells deregulates the gene expression of *Hes-1* and *Hey-1*, maybe via a CDK9-MYC-RBPJ pathway [52]. In addition, the interaction between NOTCH and NF-κB is involved in tissue damage progression [53,54]. The activation of both signaling pathways can be targeted by iBETs. In experimental kidney disease, treatment with the NOTCH inhibitor DAPT blocked NF-κB-mediated inflammation [15]. Mice lacking *Notch3* expression exhibited lower NF-κB activation in glomeruli associated to milder proteinuria, uremia, and inflammatory infiltration [49]. iBETs inhibit NF-κB activation, by binding to the acetylated lysine-310 of RelA/p65 NF-κB in nuclei, leading to ubiquitination and degradation of the constitutively active nuclear form of RelA/NF-κB [7,55]. Since Gremlin-1 activates NF-κB and NOTCH pathways in the kidney [15], the JQ1-mediated decrease of *Grem-1* transcription could secondarily inhibit the Gremlin-mediated activation of both NF-κB and NOTCH pathways, and, therefore, their contribution to CKD progression. These findings support the notion that iBETs inhibition of the NOTCH pathway could result from different molecular mechanisms.

Podocyte loss is characteristic of progressive GN [56], as we have observed in experimental NTS nephritis, and JQ1 treatment restored podocyte number in injury kidneys. In response to damage, podocytes lose their properties, including phenotype changes, leading to increased production of cytokines, growth factors and extracellular matrix components, and finally to podocyte cell death [57,58]. NOTCH activation in mature podocytes induces apoptosis [47,56]. Conditional deletion of RBPJ specifically in podocytes in mice with diabetic nephropathy is associated with reduced podocyte apoptosis [47]. In cultured podocytes, overexpression of active Notch3 led to cytoskeleton reorganization and changes to a proliferative/migratory and inflammatory phenotype [49]. In a model of conditional WT1 deletion in mature podocytes, upregulation of several NOTCH pathway components, including Hes, was associated with upregulation of genes implicated in phenotype changes [59]. These evidences suggest that inhibition of NOTCH/Hes by JQ1 could be involved in the observed beneficial effects on podocyte number preservation in experimental NTS nephritis.

Preclinical data suggest that iBETs can also diminish experimental fibrosis, as described in bleomycin-and radiation-induced lung fibrosis [60–62] and in diabetic cardiomyopathy [63]. Interestingly, integrated transcriptomics analyses across animal models of cardiac damage and human cells have found that iBETs preferentially inhibited genes of the innate inflammatory and profibrotic myocardial pathways, mainly of the NF-κB and TGF-β signaling networks [64]. Regarding experimental CKD, JQ1 decreased fibrosis in the UUO model [65,66]. Now, data presented here show that JQ1 diminished *Grem-1* overexpression in obstructed kidneys of UUO mice. Gremlin-1 has been involved in several fibrotic disorders. *In vitro*, Gremlin-1 promotes fibroblasts proliferation and extracellular matrix production. Moreover, Gremlin-1 can induce partial epithelial-to-mesenchymal transition of cultured tubular epithelial cells by activating Smad [67] and NOTCH signaling pathways [17], suggesting a potential role of Gremlin-1 in kidney fibrosis. In human ANCA-associated cGN, overexpression of Gremlin-1 correlated with tubulointerstitial fibrosis [32], suggesting that this factor can also be involved in tubulointerstitial fibrosis in this pathology. Although a limitation of the present study is that the murine NTS model studied here does not present tubulointerstitial fibrosis at the time-point studied, our findings showing that JQ1 inhibited *Grem-1* expression in the

UUO model support that the beneficial effects of iBETs can also be mediated by the inhibition of Gremlin-1-induced profibrotic events in the kidney.

Our studies using a small-molecule inhibitor targeting bromodomain proteins highlight the functional importance of bromodomain/acetyl-lysine binding as a key mechanism in orchestrating molecular interactions and regulation in chromatin biology and gene transcription. Clinical studies inhibiting BET proteins or the NOTCH system have so far focused on cancer or cardiovascular disease [68]. Actually there are several clinical trials about the role of iBETs in tumoral diseases such as solid tumors (ODM-207: NCT03035591 and ABBV-075: [69]); Metastatic Castration-resistant Prostate Cancer (ZEN-3694; [70]); refractory non-Hodgkin's lymphoma (CC-90010: NCT03220347); diffuse large B-cell lymphoma (RO6870810: NCT01987362); acute leukaemia and multiple myeloma (OTX015: NCT01713582; RO6870810: NCT02308761 and CPI-0610:NCT02157636). In patients with cardiovascular diseases such as atherosclerosis (ASSURE Trial/RVX-208: NCT01067820) or acute coronary syndrome (BETonMACE trial/Apabetalone: NCT02586155) iBETs have shown beneficial effects. In kidney diseases there is a recent open phase II study in Fabry disease to evaluate the role of RVX000222 in cardiovascular damage markers, including alkaline phosphatase levels and calcification markers, such as RANKL (NCT03228940). Our findings showing that JQ1 inhibited *Grem-1* and the NOTCH-effector gene transcription of *Hes-1* and *Hey-1* in experimental NTS nephritis, together with previous studies showing inhibition NF-κB/proinflammatory genes (as now also shown for *Ccl8*) [25], support further research on epigenetic drugs, such as iBETs, for rapidly progressive cGN.

4. Materials and Methods

4.1 Ethics Statement

All animal procedures were performed in 3-month-old C57BL/6 mice, surgeries were under isoflurane-induced anaesthesia, according to the guidelines of animal research in the European Community and with prior approval by the Animal Ethics Committee of the Health Research Institute IIS-Fundación Jiménez Díaz.

4.2. Experimental models

The BET bromodomain inhibitor JQ1, a thieno-triazolo-1,4-diazepine, was synthesized and provided collaboratively by Dr. James Bradner (Dana-Farber Cancer Institute, Boston, MA) [71]. For in vivo studies, JQ1 was dissolved in 10% hydroxypropyl β-cyclodextrin, and used at a therapeutic dose (100 mg/kg/day, i.p.), as previously described [72].

Anti-murine glomerular basement membrane (GBM) nephritis was induced in male C57BL/6 mice by administering rabbit nephrotoxic serum (NTS) as described [24]. Mice were injected with 50ul of NTS diluted 1/10 in sterile saline on day 1. Then, 4ul/g body weight were injected on day 2 and day 3, and mice were studied 10 days later. Some animals were also treated daily with JQ1 or vehicle starting one day before the first NTS administration.

For unilateral ureteral obstruction (UUO), the left ureter was ligated with silk (5/0) at two locations and cut between ligatures to prevent urinary tract infection (obstructed kidney) in male C57BL/6 mice, under isoflurane-induced anesthesia, as described [73]. Some animals were treated daily with JQ1 from 1 day before UUO, and studied after 2 and 5 days (n=6-8 mice per group). At the time of sacrifice, animals were anesthetized with 5 mg/kg xylazine (Rompun, Bayer AG) and 35 mg/kg ketamine (Ketolar, Pfizer) and the kidneys perfused in situ with cold saline before removal. Kidneys were further pro-

cessed for immunohistochemistry (fixed and paraffin-embedded), ChIP assays (fixed in 1% formaldehyde followed quenching with 0.125 M glycine), or snap-frozen in liquid nitrogen for RNA and protein studies.

4.3. Histology and immunohistochemistry

Paraffin-embedded kidney sections were stained using standard histology procedures as described elsewhere [25]. Kidney injury was evaluated by Masson staining. Extracapillary proliferation ratio was calculated by counting injured and normal glomeruli. The proportion of pathological glomeruli was evaluated by examination of at least 50 glomeruli per section, by an examiner masked to the experimental conditions.

Immunostaining was carried out in 3 μm thick tissue sections. Antigen retrieval was performed using the PTlink system (Dako) with sodium citrate buffer (10 mM) adjusted to pH 6–9, depending on the immunohistochemical marker. Endogenous peroxidase was blocked. Tissue sections were incubated for 1 h at room temperature with 4% BSA and 10% of a specific serum (depending on the secondary antibody used) in PBS to eliminate non-specific protein binding sites. Primary antibodies were incubated overnight at 4ºC. Specific biotinylated secondary antibodies (Amersham Biosciences) were used, followed by streptavidin–horseradish peroxidase conjugate, and 3,3-diaminobenzidine as a chromogen. The primary antibodies used were: F4/80 [1:50 MCA497, Bio-Rad]; WT-1 [1:100 M3561, DAKO]. Specificity was checked by omission of primary antibodies. Quantification was made by determining in five to ten randomly chosen fields (×200 magnification) the total number of positive cells using Image-Pro Plus software (data expressed as the positive-stained area relative to the total area) or quantifying manually the number of positive nuclei.

4.4. Gene expression studies

RNA from cells or renal tissue was isolated with TRItidy G™ (PanReac). cDNA was synthesized by a High Capacity cDNA Archive kit (Applied Biosystems) using 2 μg total RNA primed with random hexamer primers. Next, quantitative gene expression analysis was performed by real-time PCR on an AB7500 fast real-time PCR system (Applied Biosystems) using fluorogenic TaqMan MGB probes and primers designed by Assay-on-Demand™ gene expression products. Mouse assays IDs were: *Arg2*: Mm00477592_m1, *Cd163*: Mm00474091_m1, C*cl8*: Mm01297183_m1, *Cxcl2*: Mm00436450_m1, *Dlk1*: Mm00494477_m1, *Gremlin-1:* Mm00483888_s1, *Hes-1*: Mm01342805_m1, *Hey-1*: Mm00468865_m1, *Il10*: Mm00439616_m1, *Jagged-1:* Mm00496902, *Notch1*: Mm00435249_m1, *Notch2*: Mm00803077_m1, *Notch3*: Mm01345646_m1, *Notch4*: Mm00440525_m1, *Pai-1*: Mm00435858_m1, *Tgf-β*: Mm01178820_m1. Data were normalized to *Gapdh*: Mm99999915_g1 (Vic). The mRNA copy numbers were calculated for each sample by the instrument software using Ct value ("arithmetic fit point analysis for the lightcycler"). Results were expressed in copy numbers, calculated relative to unstimulated cells.

4.5. Protein studies

Total protein samples for frozen renal tissue were isolated in lysis buffer (50 mmol/L Tris-HCl, 150 mol/L NaCl, 2 mmol/L EDTA, 2 mmol/L EGTA, 0.2% Triton X-100, 0.3% IGEPAL, 10 μl/ml proteinase inhibitor cocktail, 0.2 mmol/L PMSF, and 0.2 mmol/L orthovanadate) as described, [25]. Proteins (20-100 μg per lane, quantified using a BCA protein assay kit) were separated on 8-12% polyacrylamide-SDS gels under reducing conditions [25]. For Western blotting, cell (50 μg/lane) protein extracts were separated on 8%–12% polyacrylamide-SDS gels under reducing conditions. Samples were then transferred onto polyvinylidene difluoride membranes (Thermo scientific), blocked with

TBS/5% non-fat milk/0.05% Tween-20, and incubated overnight at 4ºC with the following antibody (dilution): Gremlin-1 (1:1000; Sc-515877; Santa Cruz). Membranes were subsequently incubated with peroxidase-conjugated IgG secondary antibody and developed using an ECL chemiluminescence kit (Amersham). Loading controls were performed using an anti-GAPDH antibody (1:5000; CB1001, Millipore). Results were analyzed by LAS 4000 and Amersham Imager 600 (GEHealthcare) and densitometered by Quantity One software (Biorad). The evaluation of CCL8 in kidney tissue was done by ELISA (R&D system, Cat. No. DY790) following the instructions provided by the manufacturer.

4.6. Chromatin immunoprecipitation

Kidneys were fixed in 1% formaldehyde (Sigma-Aldrich) followed by quenching with 0.125M glycine. DNA fragments 500-1000 bp long were generated on a BioRuptor (Diagenode) and ChIP assays were performed using the High Cell ChIP kit (Diagenode) following the manufacturer´s instructions. The antibodies used were BRD4 (Bethyl Laboratories) and normal IgG as negative control (Millipore). Immunoprecipitated DNA was analyzed by quantitative RT-PCR using the following primers of *Grem-1* promoter; forward, 5´-GACCAATGGAGAGACGCAGT-3´ and reverse, 5´-GTTCTTCGCTGTGGACGAGT-3´. Chromatin obtained before immunoprecipitation was used as the input control. Relative enrichment was calculated as the percentage of input DNA for each sample using the formula % input = 2 exp [(Ct unbound) – $\log_2$ (unbound dilution factor) – Ct bound)] x 100 and normalized to normal rabbit IgG antibody (considered as 1).

4.7. Statistical analysis

Results are expressed as mean±SEM of the n-fold increase with respect to the control (represented as 1). In the NTS nephritis model, data were obtained normalizing NTS and NTS +JQ1 kidneys versus control average. In the UUO model, data were obtained comparing obstructed kidneys versus untreated contralateral kidneys (represented as 1). The Shapiro-Wilk test was used to evaluate sample normality distribution. If the samples followed the Gaussian distribution, a one-way ANOVA followed by the corresponding post-hoc analyses, were used. To compare non-parametric samples, a Kruskal-Wallis and a subsequent post-hoc analysis was performed. Statistical analysis was conducted using GraphPad Prism 8.0 (GrahPad Software, San Diego California United States). Values of p < 0.05 were considered statistically significant.

Author Contributions: Conceptualization, L. T-S, B. S-A, JL. M-P, S. M, M. R-O and S. R-M; Data curation, L. T-S, JL. M-P, L. M-E, B. S-A, and S. R-M; Formal analysis, JL. M-P, B. S-A, R. R-D, C. L-L, M. R-O and S. R-M; Funding acquisition, B. S-A, C. L-L, A. O, M. R-O, S. R-M and R. R-D; Investigation, JL. M-P, S. R-M, M. R-O and R. R-D; Methodology: JL. M-P, B. S-A, L. T-S, A. T-M, L. M-E, V.M, R. R-D S. R-M, and M. R-O and; Project administration, M. R-O; Resources, B. S-A, C. L-L, R. R-D, , S. M, M. R-O and A. O; Supervision, M. R-O; Validation, C. L-L, and A. O; Visualization, M. R-O, C. L-L, and A. O Diez; Writing – original draft, M. R-O, JL. M-P, and L. T-S; Writing – review & editing, B. S-A, C. L-L, L. M-E, A. T-M, V. M, A. S, GM. F-J. S. M, S. R-M, and A. O.

Funding: This research was funded by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119, PI17/01411, PI20/00140, PI19/00184, PI20/00639; and DTS20/00083). Sara Borrell' program from Instituto de Salud Carlos III (ISCIII) (grant number CD20/00042 to R.R.R-D). Red de Investigación Renal REDINREN: RD16/0009/0003 to M.R-O and RD16/0009/0020 to C.L-L. Sociedad Española de Nefrología. "NOVELREN-CM: Enfermedad renal crónica: nuevas Estrategias para la prevención, Diagnóstico y tratamiento" (B2017/BMD-3751 to M.R-O). "Convocatoria Dinamización Europa Investigación 2019" MINECO (EIN2019-103294 to M.R-O and S.R-M); Juan de la Cierva incorporacion grant: IJC2018-035187-I to S.R-M, Innovation pro-gramme under the Marie Skłodowska-Curie grant of the European Union's Horizon 2020 (IMProve-PD ID: 812699) to M.R-O. Fundacion Conchita Rabago to L.T-S.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the IIS-FJD Animal Research Ethical Committee guidelines (PROEX 065/18).

Acknowledgments: We want to thank Irene Rubio Soto for her help in the immunohisto-chemical techniques, and Dr. Pierre-Louis Tharaux (Paris Cardiovascular Centre - PARCC, IN-SERM) for his help with the NTS model development. The BET bromodomain inhibitor JQ1, a thieno-triazolo-1,4-diazepine, was synthesized and kindly provided by Dr. James Bradner (Da-na-Farber Cancer Institute, Boston, MA).

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Stevens, P.E.; Levin, A.; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline. *Ann. Intern. Med.* **2013**, *158*, 825–830, doi:10.7326/0003-4819-158-11-201306040-00007.

2. Parmar, M.S.; Bas*hir, K. Crescentic Glomerulonephritis. StatPearls*; **2021.**

3. Ortiz, A. RICORS2040: The Need for Collaborative Research in Chronic Kidney Disease. *Clin. Kidney J.***2021**, doi:10.1093/ckj/sfab170.

4. Foreman, K.J.; Marquez, N.; Dolgert, A.; Fukutaki, K.; Fullman, N.; McGaughey, M.; Pletcher, M.A.; Smith, A.E.; Tang, K.; Yuan, C.-W.; et al. Forecasting Life Expectancy, Years of Life Lost, and All-Cause and Cause-Specific Mortality for 250 Causes of Death: Reference and Alternative Scenarios for 2016-40 for 195 Countries and Territories. *Lancet.* **2018**, *392*, 2052–2090, doi:10.1016/S0140-6736(18)31694-5.

5. Jennette, J.C.; Nachman, P.H. ANCA Glomerulonephritis and Vasculitis. *Clin. j. Am. Soc. Nephrol. : CJASN* **2017**, *12*, 1680–1691, doi:10.2215/CJN.02500317.

6. Sanchez, R.; Zhou, M.-M. The Role of Human Bromodomains in Chromatin Biology and Gene Transcription. *Curr. opin. drug discov. dev.***2009**, *12*, 659–665.

7. Zou, Z.; Huang, B.; Wu, X.; Zhang, H.; Qi, J.; Bradner, J.; Nair, S.; Chen, L.-F. Brd4 Maintains Constitutively Active NF-ĸB in Cancer Cells by Binding to Acetylated RelA. *Oncogene* **2014**, *33*, 2395–2404, doi:10.1038/onc.2013.179.

8. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W.B.; Fedorov, O.; Morse, E.M.; Keates, T.; Hickman, T.T.; Felletar, I.; et al. Selective Inhibition of BET Bromodomains. *Nature* **2010**, *468*, 1067–1073, doi:10.1038/nature09504.

9. Nicodeme, E.; Jeffrey, K.L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C.-W.; Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; et al. Suppression of Inflammation by a Synthetic Histone Mimic. *Nature* **2010**, *468*, 1119–1123, doi:10.1038/nature09589.

10.   Morgado-Pascual, J.L.; Rayego-Mateos, S.; Tejedor, L.; Suarez-Alvarez, B.; Ruiz-Ortega, M. Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases. *Front. Pharmacol.* **2019**, *10*, 1315, doi:10.3389/fphar.2019.01315.

11.   Morgado-Pascual, J.L.; Marchant, V.; Rodrigues-Diez, R.; Dolade, N.; Suarez-Alvarez, B.; Kerr, B.; Valdivielso, J.M.; Ruiz-Ortega, M.; Rayego-Mateos, S. Epigenetic Modification Mechanisms Involved in Inflammation and Fibrosis in Renal Pathology. *Mediat. Inflamm.* **2018**, *2018*, 2931049, doi:10.1155/2018/2931049.

12.   Hénique, C.; Papista, C.; Guyonnet, L.; Lenoir, O.; Tharaux, P.-L. Update on Crescentic Glomerulonephritis. *Semin. Immunopathol.* **2014**, *36*, 479–490, doi:10.1007/s00281-014-0435-7.

13.   Droguett, A.; Valderrama, G.; Burgos, M.E.; Carpio, D.; Saka, C.; Egido, J.; Ruiz-Ortega, M.; Mezzano, S. Gremlin, A Potential Urinary Biomarker of Anca-Associated Crescentic Glomerulonephritis. *Sci. Rep.* **2019**, *9*, 6867, doi:10.1038/s41598-019-43358-5.

14.   Mezzano, S.; Droguett, A.; Lavoz, C.; Krall, P.; Egido, J.; Ruiz-Ortega, M. Gremlin and Renal Diseases: Ready to Jump the Fence to Clinical Utility? *Nephrol. Dial. Transplant.* **2018**, *33*, 735–741, doi:10.1093/ndt/gfx194.

15.   Lavoz, C.; Poveda, J.; Marquez-Exposito, L.; Rayego-Mateos, S.; Rodrigues-Diez, R.R.; Ortiz, A.; Egido, J.; Mezzano, S.; Ruiz-Ortega, M. Gremlin Activates the Notch Pathway Linked to Renal Inflammation. *Clin. Sci..* **2018**, *132*, 1097–1115, doi:10.1042/CS20171553.

16.   Lavoz, C.; Alique, M.; Rodrigues-Diez, R.; Pato, J.; Keri, G.; Mezzano, S.; Egido, J.; Ruiz-Ortega, M. Gremlin Regulates Renal Inflammation via the Vascular Endothelial Growth Factor Receptor 2 Pathway. *J. Pathol.* **2015**, *236*, 407–420, doi:10.1002/path.4537.

17.   Marquez-Exposito, L.; Lavoz, C.; Rodrigues-Diez, R.R.; Rayego-Mateos, S.; Orejudo, M.; Cantero-Navarro, E.; Ortiz, A.; Egido, J.; Selgas, R.; Mezzano, S.; et al. Gremlin Regulates Tubular Epithelial to Mesenchymal Transition via VEGFR2: Potential Role in Renal Fibrosis. *Front. Pharmacol.* **2018**, *9*, 1195, doi:10.3389/fphar.2018.01195.

18.   Marquez-Exposito, L.; Cantero-Navarro, E.; R Rodrigues-Diez, R.; Orejudo, M.; Tejera-Muñoz, A.; Tejedor, L.; Rayego-Mateos, S.; Rández-Carbayo, J.; Santos-Sanchez, L.; Mezzano, S.; et al. Molecular Regulation of Notch Signaling by Gremlin. *Advances in experimental medicine and biology* **2020**, *1227*, 81–94, doi:10.1007/978-3-030-36422-9_6.

19.   Walsh, D.W.; Roxburgh, S.A.; McGettigan, P.; Berthier, C.C.; Higgins, D.G.; Kretzler, M.; Cohen, C.D.; Mezzano, S.; Brazil, D.P.; Martin, F. Co-Regulation of Gremlin and Notch Signalling in Diabetic Nephropathy. *Biochimica et biophysica acta* **2008**, *1782*, 10–21, doi:10.1016/j.bbadis.2007.09.005.

20.   Murea, M.; Park, J.-K.; Sharma, S.; Kato, H.; Gruenwald, A.; Niranjan, T.; Si, H.; Thomas, D.B.; Pullman, J.M.; Melamed, M.L.; et al. Expression of Notch Pathway Proteins Correlates with Albuminuria, Glomerulosclerosis, and Renal Function. *Kidney Int.* **2010**, *78*, 514–522, doi:10.1038/ki.2010.172.

21.   Sirin, Y.; Susztak, K. Notch in the Kidney: Development and Disease. *J. Pathol.* **2012**, *226*, 394–403, doi:10.1002/path.2967.

22.   Lavoz, C.; Droguett, A.; Burgos, M.E.; Carpio, D.J.; Ortiz, A.; Egido, J.; Mezzano, S.; Ruiz-Ortega, M. Translational Study of the Notch Pathway in Hypertensive Nephropathy. *Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia* **2014**, *34*, 369–376, doi:10.3265/Nefrologia.pre2014.Jan.12436.

23.   Marquez-Exposito, L.; Cantero-Navarro, E.; Lavoz, C.; Fierro-Fernández, M.; Poveda, J.; Rayego-Mateos, S.; Rodrigues-Diez, R.R.; Morgado-Pascual, J.L.; Orejudo, M.; Mezzano, S.; et al. Could Notch Signaling Pathway Be a Potential Therapeutic Option in Renal Diseases? *Nefrologia.* **2018.** 38, 466–475, doi:10.1016/j.nefro.2017.11.027.

24.   Bollée, G.; Flamant, M.; Schordan, S.; Fligny, C.; Rumpel, E.; Milon, M.; Schordan, E.; Sabaa, N.; Vandermeersch, S.; Galaup, A.; et al. Epidermal Growth Factor Receptor Promotes Glomerular Injury and Renal Failure in Rapidly Progressive Crescentic Glomerulonephritis. *Nat. Med.* **2011**, *17*, 1242–1250, doi:10.1038/nm.2491.

25.   Suarez-Alvarez, B.; Morgado-Pascual, J.L.; Rayego-Mateos, S.; Rodriguez, R.M.; Rodrigues-Diez, R.; Cannata-Ortiz, P.; Sanz, A.B.; Egido, J.; Tharaux, P.-L.; Ortiz, A.; et al. Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage. *J. Am. Soc. Nephrol. : JASN.* **2017**, *28*, 504–519, doi:10.1681/ASN.2015080910.

26.   Bielesz, B.; Sirin, Y.; Si, H.; Niranjan, T.; Gruenwald, A.; Ahn, S.; Kato, H.; Pullman, J.; Gessler, M.; Haase, V.H.; et al. Epithelial Notch Signaling Regulates Interstitial Fibrosis Development in the Kidneys of Mice and Humans. *J. Clin. Investig.* **2010**, *120*, 4040–4054, doi:10.1172/JCI43025.

27.   Marquez-Exposito, L.; Rodrigues-Diez, R.R.; Rayego-Mateos, S.; Fierro-Fernandez, M.; Rodrigues-Diez, R.; Orejudo, M.; Santos-Sanchez, L.; Blanco, E.M.; Laborda, J.; Mezzano, S.; et al. Deletion of Delta-like 1 Homologue Accelerates Renal Inflammation by Modulating the Th17 Immune Response. *FASEB J.* **2021**, *35*, e21213, doi:10.1096/fj.201903131R.

28.   Huang, S.; Park, J.; Qiu, C.; Chung, K.W.; Li, S.-Y.; Sirin, Y.; Han, S.H.; Taylor, V.; Zimber-Strobl, U.; Susztak, K. Jagged1/Notch2 Controls Kidney Fibrosis via Tfam-Mediated Metabolic Reprogramming. *PLoS Biol.* **2018**, *16*, e2005233, doi:10.1371/journal.pbio.2005233.

29.   Brix, S.R.; Stege, G.; Disteldorf, E.; Hoxha, E.; Krebs, C.; Krohn, S.; Otto, B.; Klätschke, K.; Herden, E.; Heymann, F.; et al. CC Chemokine Ligand 18 in ANCA-Associated Crescentic GN. *J. Am. Soc. Nephrol. : JASN.* **2015**, *26*, 2105–2117, doi:10.1681/ASN.2014040407.

30.   Cantero-Navarro, E.; Rayego-Mateos, S.; Orejudo, M.; Tejedor-Santamaria, L.; Tejera-Muñoz, A.; Sanz, A.B.; Marquez-Exposito, L.; Marchant, V.; Santos-Sanchez, L.; Egido, J.; et al. Role of Macrophages and Related Cytokines in Kidney Disease. *Front. Med.* **2021**, *8*, 688060, doi:10.3389/fmed.2021.688060.

31.   Islam, S.A.; Ling, M.F.; Leung, J.; Shreffler, W.G.; Luster, A.D. Identification of Human CCR8 as a CCL18 Receptor. *Exp. Med.* **2013**, *210*, 1889–1898, doi:10.1084/jem.20130240.

32.   Mezzano, S.; Droguett, A.; Burgos, M.E.; Aros, C.; Ardiles, L.; Flores, C.; Carpio, D.; Carvajal, G.; Ruiz-Ortega, M.; Egido, J. Expression of Gremlin, a Bone Morphogenetic Protein Antagonist, in Glomerular Crescents of Pauci-Immune Glomerulonephritis. *Nephrol. Dial. Transplant.* **2007**, *22*, 1882–1890, doi:10.1093/ndt/gfm145.

33.   Ucero, A.C.; Benito-Martin, A.; Izquierdo, M.C.; Sanchez-Niño, M.D.; Sanz, A.B.; Ramos, A.M.; Berzal, S.; Ruiz-Ortega, M.; Egido, J.; Ortiz, A. Unilateral Ureteral Obstruction: Beyond Obstruction. *Int. Urol. Nephrol.* **2014**, *46*, 765–776, doi:10.1007/s11255-013-0520-1.

34.   Delmore, J.E.; Issa, G.C.; Lemieux, M.E.; Rahl, P.B.; Shi, J.; Jacobs, H.M.; Kastritis, E.; Gilpatrick, T.; Paranal, R.M.; Qi, J.; et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target C-Myc. *Cell* **2011**, *146*, 904–917, doi:10.1016/j.cell.2011.08.017.

35.   Dolan, V.; Murphy, M.; Sadlier, D.; Lappin, D.; Doran, P.; Godson, C.; Martin, F.; O'Meara, Y.; Schmid, H.; Henger, A.; et al. Expression of Gremlin, a Bone Morphogenetic Protein Antagonist, in Human Diabetic Nephropathy. *Am. J. Kidney Dis.* **2005**, *45*, 1034–1039, doi:10.1053/j.ajkd.2005.03.014.

36.   Carvajal, G.; Droguett, A.; Burgos, M.E.; Aros, C.; Ardiles, L.; Flores, C.; Carpio, D.; Ruiz-Ortega, M.; Egido, J.; Mezzano, S. Gremlin: A Novel Mediator of Epithelial Mesenchymal Transition and Fibrosis in Chronic Allograft Nephropathy. *Transplant. Proc.* **2008**, *40*, 734–739, doi:10.1016/j.transproceed.2008.02.064.

37.   Roxburgh, S.A.; Kattla, J.J.; Curran, S.P.; O'Meara, Y.M.; Pollock, C.A.; Goldschmeding, R.; Godson, C.; Martin, F.; Brazil, D.P. Allelic Depletion of Grem1 Attenuates Diabetic Kidney Disease. *Diabetes* **2009**, *58*, 1641–1650, doi:10.2337/db08-1365.

38.   Rodrigues-Diez, R.; Lavoz, C.; Carvajal, G.; Rayego-Mateos, S.; Rodrigues Diez, R.R.; Ortiz, A.; Egido, J.; Mezzano, S.; Ruiz-Ortega, M. Gremlin Is a Downstream Profibrotic Mediator of Transforming Growth Factor-Beta in Cultured Renal Cells. *Nephron. Experimental nephrology* **2012**, *122*, 62–74, doi:10.1159/000346575.

39.   Droguett, A.; Krall, P.; Burgos, M.E.; Valderrama, G.; Carpio, D.; Ardiles, L.; Rodriguez-Diez, R.; Kerr, B.; Walz, K.; Ruiz-Ortega, M.; et al. Tubular Overexpression of Gremlin Induces Renal Damage Susceptibility in Mice. *PloS one* **2014**, *9*, e101879, doi:10.1371/journal.pone.0101879.

40.   Marchant, V.; Droguett, A.; Valderrama, G.; Burgos, M.E.; Carpio, D.; Kerr, B.; Ruiz-Ortega, M.; Egido, J.; Mezzano, S. Tubular Overexpression of Gremlin in Transgenic Mice Aggravates Renal Damage in Diabetic Nephropathy. *Am. J. Physiol. Renal Physiol.***2015**, *309*, F559-68, doi:10.1152/ajprenal.00023.2015.

41.   Church, R.H.; Ali, I.; Tate, M.; Lavin, D.; Krishnakumar, A.; Kok, H.M.; Hombrebueno, J.R.; Dunne, P.D.; Bingham, V.; Goldschmeding, R.; et al. Gremlin1 Plays a Key Role in Kidney Development and Renal Fibrosis. *Am. J. Physiol. Renal Physiol.***2017**, *312*, F1141–F1157, doi:10.1152/ajprenal.00344.2016.

42.   Lavoz, C.; Rodrigues-Diez, R.R.; Plaza, A.; Carpio, D.; Egido, J.; Ruiz-Ortega, M.; Mezzano, S. VEGFR2 Blockade Improves Renal Damage in an Experimental Model of Type 2 Diabetic Nephropathy. *J. Clin. Med.* **2020**, *9*, doi:10.3390/jcm9020302.

43.   Chenivesse, C.; Tsicopoulos, A. CCL18 - Beyond Chemotaxis. *Cytokine* **2018**, *109*, 52–56, doi:10.1016/j.cyto.2018.01.023.

44.   Little, A.C.; Pathanjeli, P.; Wu, Z.; Bao, L.; Goo, L.E.; Yates, J.A.; Oliver, C.R.; Soellner, M.B.; Merajver, S.D. IL-4/IL-13 Stimulated Macrophages Enhance Breast Cancer Invasion Via Rho-GTPase Regulation of Synergistic VEGF/CCL-18 Signaling. *Front. Oncol.* **2019**, *9*, 456, doi:10.3389/fonc.2019.00456.

45.   Yokoe, Y.; Tsuboi, N.; Imaizumi, T.; Kitagawa, A.; Karasawa, M.; Ozeki, T.; Endo, N.; Sawa, Y.; Kato, S.; Katsuno, T.; et al. Clinical Impact of Urinary CD11b and CD163 on the Renal Outcomes of Anti-Neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. *Nephrol. Dial. Transplant.***2021**, *36*, 1452–1463, doi:10.1093/ndt/gfaa097.

46.   Villacorta, J.; Lucientes, L.; Goicoechea, E.; Acevedo, M.; Cavero, T.; Sanchez-Camara, L.; Díaz-Crespo, F.; Gimenez-Moyano, S.; García-Bermejo, L.; Fernandez-Juarez, G. Urinary Soluble CD163 as a Biomarker of Disease Activity and Relapse in Antineutrophil Cytoplasm Antibody-Associated Glomerulonephritis. *Clin. Kidney J.***2021**, *14*, 212–219, doi:10.1093/ckj/sfaa043.

47.   Niranjan, T.; Bielesz, B.; Gruenwald, A.; Ponda, M.P.; Kopp, J.B.; Thomas, D.B.; Susztak, K. The Notch Pathway in Podocytes Plays a Role in the Development of Glomerular Disease. *Nat. Med.* **2008**, *14*, 290–298, doi:10.1038/nm1731.

48.   Waters, A.M.; Wu, M.Y.J.; Onay, T.; Scutaru, J.; Liu, J.; Lobe, C.G.; Quaggin, S.E.; Piscione, T.D. Ectopic Notch Activation in Developing Podocytes Causes Glomerulosclerosis. *J. Am. Soc. Nephrol. : JASN.* **2008**, *19*, 1139–1157, doi:10.1681/ASN.2007050596.

49.   el Machhour, F.; Keuylian, Z.; Kavvadas, P.; Dussaule, J.-C.; Chatziantoniou, C. Activation of Notch3 in Glomeruli Promotes the Development of Rapidly Progressive Renal Disease. *J. Am. Soc. Nephrol. : JASN.* **2015**, *26*, 1561–1575, doi:10.1681/ASN.2013090968.

50.   Tao, Z.; Li, X.; Wang, H.; Chen, G.; Feng, Z.; Wu, Y.; Yin, H.; Zhao, G.; Deng, Z.; Zhao, C.; et al. BRD4 Regulates Self-Renewal Ability and Tumorigenicity of Glioma-Initiating Cells by Enrichment in the Notch1 Promoter Region. *Clinical and translational medicine* **2020**, *10*, e181, doi:10.1002/ctm2.181.

51.   Lai, J.; Liu, Z.; Zhao, Y.; Ma, C.; Huang, H. Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins. *Front. Oncol.* **2021**, *11*, 716830, doi:10.3389/fonc.2021.716830.

52.   Xie, Q.; Wu, Q.; Kim, L.; Miller, T.E.; Liau, B.B.; Mack, S.C.; Yang, K.; Factor, D.C.; Fang, X.; Huang, Z.; et al. RBPJ Maintains Brain Tumor-Initiating Cells through CDK9-Mediated Transcriptional Elongation. *J. Clin. Investig.***2016**, *126*, 2757–2772, doi:10.1172/JCI86114.

53.   Ferrandino, F.; Grazioli, P.; Bellavia, D.; Campese, A.F.; Screpanti, I.; Felli, M.P. Notch and NF-KB: Coach and Players of Regulatory T-Cell Response in Cancer. *Front. immunol.* **2018**, *9*, 2165, doi:10.3389/fimmu.2018.02165.

54.   Saito, T.; Tanaka, S. Molecular Mechanisms Underlying Osteoarthritis Development: Notch and NF-KB. *Arthritis Res. Ther.***2017**, *19*, 94, doi:10.1186/s13075-017-1296-y.

55.   Hajmirza, A.; Emadali, A.; Gauthier, A.; Casasnovas, O.; Gressin, R.; Callanan, M.B. BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer. *Biomedicines* **2018**, *6*, doi:10.3390/biomedicines6010016.

56.   Schiffer, M.; Bitzer, M.; Roberts, I.S.; Kopp, J.B.; ten Dijke, P.; Mundel, P.; Böttinger, E.P. Apoptosis in Podocytes Induced by TGF-Beta and Smad7. *J. Clin. Investig.***2001**, *108*, 807–816, doi:10.1172/JCI12367.

57.   Garg, P. A Review of Podocyte Biology. *Am. J. Nephrol.* **2018**, *47 Suppl 1*, 3–13, doi:10.1159/000481633.

58.   Cellesi, F.; Li, M.; Rastaldi, M.P. Podocyte Injury and Repair Mechanisms. *Curr. Opin. Nephrol. Hypertens.***2015**, *24*, 239–244, doi:10.1097/MNH.0000000000000124.

59.   Asfahani, R.I.; Tahoun, M.M.; Miller-Hodges, E. v; Bellerby, J.; Virasami, A.K.; Sampson, R.D.; Moulding, D.; Sebire, N.J.; Hohenstein, P.; Scambler, P.J.; et al. Activation of Podocyte Notch Mediates Early Wt1 Glomerulopathy. *Kidney Int.* **2018**, *93*, 903–920, doi:10.1016/j.kint.2017.11.014.

60.   Tang, X.; Peng, R.; Ren, Y.; Apparsundaram, S.; Deguzman, J.; Bauer, C.M.; Hoffman, A.F.; Hamilton, S.; Liang, Z.; Zeng, H.; et al. BET Bromodomain Proteins Mediate Downstream Signaling Events Following Growth Factor Stimulation in Human Lung Fibroblasts and Are Involved in Bleomycin-Induced Pulmonary Fibrosis. *Mol. Pharmacol.* **2013**, *83*, 283–293, doi:10.1124/mol.112.081661.

61.   Tang, X.; Peng, R.; Phillips, J.E.; Deguzman, J.; Ren, Y.; Apparsundaram, S.; Luo, Q.; Bauer, C.M.; Fuentes, M.E.; DeMartino, J.A.; et al. Assessment of Brd4 Inhibition in Idiopathic Pulmonary Fibrosis Lung Fibroblasts and in Vivo Models of Lung Fibrosis. *Am. J. Clin. Pathol.* **2013**, *183*, 470–479, doi:10.1016/j.ajpath.2013.04.020.

62.   Wang, J.; Zhou, F.; Li, Z.; Mei, H.; Wang, Y.; Ma, H.; Shi, L.; Huang, A.; Zhang, T.; Lin, Z.; et al. Pharmacological Targeting of BET Proteins Attenuates Radiation-Induced Lung Fibrosis. *Sci. Rep.* **2018**, *8*, 998, doi:10.1038/s41598-018-19343-9.

63.   Guo, M.; Wang, H.-X.; Chen, W.-J. BET-Inhibition by JQ1 Alleviates Streptozotocin-Induced Diabetic Cardiomyopathy. *Toxicol. Appl. Pharmacol.***2018**, *352*, 9–18, doi:10.1016/j.taap.2018.05.018.

64.   Duan, Q.; McMahon, S.; Anand, P.; Shah, H.; Thomas, S.; Salunga, H.T.; Huang, Y.; Zhang, R.; Sahadevan, A.; Lemieux, M.E.; et al. BET Bromodomain Inhibition Suppresses Innate Inflammatory and Profibrotic Transcriptional Networks in Heart Failure. *Sci. Transl. Med.***2017**, *9*, doi:10.1126/scitranslmed.aah5084.

65.   Zhou, B.; Mu, J.; Gong, Y.; Lu, C.; Zhao, Y.; He, T.; Qin, Z. Brd4 Inhibition Attenuates Unilateral Ureteral Obstruction-Induced Fibrosis by Blocking TGF-β-Mediated Nox4 Expression. *Redox Biol.* **2017**, *11*, 390–402, doi:10.1016/j.redox.2016.12.031.

66.   Xiong, C.; Masucci, M. v; Zhou, X.; Liu, N.; Zang, X.; Tolbert, E.; Zhao, T.C.; Zhuang, S. Pharmacological Targeting of BET Proteins Inhibits Renal Fibroblast Activation and Alleviates Renal Fibrosis. *Oncotarget* **2016**, *7*, 69291–69308, doi:10.18632/oncotarget.12498.

67.   Rodrigues-Diez, R.; Rodrigues-Diez, R.R.; Lavoz, C.; Carvajal, G.; Droguett, A.; Garcia-Redondo, A.B.; Rodriguez, I.; Ortiz, A.; Egido, J.; Mezzano, S.; et al. Gremlin Activates the Smad Pathway Linked to Epithelial Mesenchymal Transdifferentiation in Cultured Tubular Epithelial Cells. *Biomed Res. Int.***2014**, *2014*, 802841, doi:10.1155/2014/802841.

68.   Christopoulos, P.F.; Gjølberg, T.T.; Krüger, S.; Haraldsen, G.; Andersen, J.T.; Sundlisæter, E. Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases. *Front. immunol.* **2021**, *12*, 668207, doi:10.3389/fimmu.2021.668207.

69.   Piha-Paul, S.A.; Sachdev, J.C.; Barve, M.; LoRusso, P.; Szmulewitz, R.; Patel, S.P.; Lara, P.N.; Chen, X.; Hu, B.; Freise, K.J.; et al. First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. *Clin. Cancer Res.***2019**, *25*, 6309–6319, doi:10.1158/1078-0432.CCR-19-0578.

70.   Aggarwal, R.R.; Schweizer, M.T.; Nanus, D.M.; Pantuck, A.J.; Heath, E.I.; Campeau, E.; Attwell, S.; Norek, K.; Snyder, M.; Bauman, L.; et al. A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. *Clin. Cancer Res.***2020**, *26*, 5338–5347, doi:10.1158/1078-0432.CCR-20-1707.

71.   Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J.-P.; Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Müller, S.; Pawson, T.; et al. Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family. *Cell* **2012**, *149*, 214–231, doi:10.1016/j.cell.2012.02.013.

72.   Klein, K.; Kabala, P.A.; Grabiec, A.M.; Gay, R.E.; Kolling, C.; Lin, L.-L.; Gay, S.; Tak, P.P.; Prinjha, R.K.; Ospelt, C.; et al. The Bromodomain Protein Inhibitor I-BET151 Suppresses Expression of Inflammatory Genes and Matrix Degrading Enzymes in Rheumatoid Arthritis Synovial Fibroblasts. *Ann. Rheum. Dis.***2016**, *75*, 422–429, doi:10.1136/annrheumdis-2014-205809.

73.   Esteban, V.; Ruperez, M.; Vita, J.R.; López, E.S.; Mezzano, S.; Plaza, J.J.; Egido, J.; Ruiz-Ortega, M. Effect of Simultaneous Blockade of AT1 and AT2 Receptors on the NFkappaB Pathway and Renal Inflammatory Response. *Kidney Int.. Supplement* **2003**, S33-8, doi:10.1046/j.1523-1755.64.s86.7.x.